Matinas BioPharma Holdings, Inc.
MTNB
$0.65
$0.0599.98%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -35.17% | -32.05% | -5.28% | -13.20% | -5.22% |
| Gross Profit | 35.17% | 32.05% | 5.28% | -19.90% | -30.71% |
| SG&A Expenses | -25.20% | -24.55% | -5.08% | -9.44% | -16.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.41% | -28.58% | -5.20% | -11.67% | -10.03% |
| Operating Income | 31.41% | 28.58% | 5.20% | -5.66% | -7.43% |
| Income Before Tax | -60.20% | 29.40% | 5.63% | -5.64% | -46.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.69% | 29.40% | 5.63% | -5.64% | -46.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.69% | 29.40% | 5.63% | -5.64% | -46.23% |
| EBIT | 31.41% | 28.58% | 5.20% | -5.66% | -7.43% |
| EBITDA | 31.82% | 28.92% | 5.18% | -5.79% | -7.54% |
| EPS Basic | -35.51% | 39.10% | 17.77% | -5.60% | -45.01% |
| Normalized Basic EPS | 34.40% | 39.10% | 17.77% | -5.59% | -45.00% |
| EPS Diluted | -35.51% | 39.10% | 17.77% | -5.60% | -45.01% |
| Normalized Diluted EPS | 34.40% | 39.10% | 17.77% | -5.59% | -45.00% |
| Average Basic Shares Outstanding | 17.11% | 15.94% | 14.77% | 0.04% | 0.84% |
| Average Diluted Shares Outstanding | 17.11% | 15.94% | 14.77% | 0.04% | 0.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |